Announcements Trials
Browse Landscape

Phase

Phase 2 5Phase 3 3Phase 1 2

Status

Terminated 1Recruiting 1Not yet recruiting 1

Sponsor Class

INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Thoracic 3

Conditions

Carcinoma, Non-Small-Cell Lung 19Carcinoma 4NSCLC 3Lung Neoplasms 3Neoplasm Metastasis 2Stage IB-IIIA Non-small Cell Lung Carcinoma 1Non-small Cell Carcinoma 1Neoplasms 1Neoplasm, Residual 1NSCLC Patients With Brain Metastasis 1Locally Advanced or Metastatic Non-squamous NSCLC 1Locally Advanced or Metastatic EGFR T790M+ NSCLC 1Locally Advanced or Metastatic EGFR Sensitising Mutation Positive Non Small Cell Lung Cancer 1Bronchial Neoplasms 1Brain Neoplasms 1Anticancer Treatment 1

Interventions

osimertinib 3Vinorelbine 3Pemetrexed 3Cisplatin 3Carboplatin 3Gemcitabine 2Gefitinib 2Docetaxel 2CP protocol 2rezivertinib 1pembrolizumab 1aumolertinib 1Taxes 1Paclitaxel 1HMPL-013 1HM781-36B 1Erlotinib Hydrochloride 1Albumin-Bound Paclitaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 3 × NSCLC × osimertinib × Clear all
NCT07376382 2026-05-13

SYNSTAR-02

CSPC Megalith Biopharmaceutical Co.,Ltd.

Phase 3 Not yet recruiting
680 enrolled
Thoracic

NSCLC

NCT05493501 2024-05-02

Aumolertinib With Chemotherapy or Alone Compared With Osimertinib in Patients With Epidermal Growth Factor Receptor-Mutant Non-Small Cell Lung Cancer

EQRx International, Inc.

Phase 3 Terminated
8 enrolled 7 charts
Thoracic

NSCLC

NCT05382728 2024-01-30

Phase III Study of TY-9591 in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer (FLETEO)

TYK Medicines, Inc

Phase 3 Recruiting
680 enrolled
Thoracic

NSCLC

Data powered by HemOnc (CC BY 4.0) Colophon âš¡